Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 ADA [3] Purine metabolism, Metabolic pathways, Primary immunodeficiency D11017 Elapegademase [1] 65
2 ADH1A [9] Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease D00707 Fomepizole [1] 301
3 ADH1B [9] Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease D00707 Fomepizole [1] 301
4 ADH1C [9] Glycolysis / Gluconeogenesis, Fatty acid degradation, Tyrosine metabolism, Pyruvate metabolism, Retinol metabolism, Metabolism of xenobiotics by cytochrome P450, Drug metabolism - cytochrome P450, Metabolic pathways, Alcoholic liver disease D00707 Fomepizole [1] 301
5 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00045 Adenosine [3] 13, 58, 65
6 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00227 Aminophylline [1] 63
7 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00371 Theophylline [2] 236, 299
8 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
9 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
10 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01712 Theophylline [2] 236, 299
11 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02017 Theophylline [2] 236, 299
12 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D02769 Adenosine phosphate [1] 46
13 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D05429 Aminophylline [1] 63
14 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06103 Theophylline [2] 236, 299
15 ADORA1 [7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D06104 Theophylline [2] 236, 299
16 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00045 Adenosine [3] 13, 58, 65
17 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
18 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine [9] 2, 6, 13, 21, 46, 78, 96, 97, 265
19 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D02017 Theophylline [2] 236, 299
20 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D02769 Adenosine phosphate [1] 46
21 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D04641 Istradefylline [1] 6
22 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D05711 Regadenoson [1] 58
23 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D09717 Preladenant [1] 6
24 ADORA2A [7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D10174 Tozadenant [1] 6
25 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00045 Adenosine [3] 13, 58, 65
26 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00227 Aminophylline [1] 63
27 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00371 Theophylline [2] 236, 299
28 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D01712 Theophylline [2] 236, 299
29 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D02769 Adenosine phosphate [1] 46
30 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D05429 Aminophylline [1] 63
31 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D06103 Theophylline [2] 236, 299
32 ADORA2B [5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D06104 Theophylline [2] 236, 299
33 ADORA3 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine [3] 13, 58, 65
34 ADORA3 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02769 Adenosine phosphate [1] 46
35 ADORA3 [3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10971 Piclidenoson [1] 46
36 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
37 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
38 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
39 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
40 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
41 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
42 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
43 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
44 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
45 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
46 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
47 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
48 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
49 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
50 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
51 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
52 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
53 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
54 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
55 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
56 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
57 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
58 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
59 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
60 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
61 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
62 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
63 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
64 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
65 ADRA1D [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
66 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
67 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
68 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
69 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
70 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
71 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
72 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
73 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
74 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
75 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
76 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
77 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
78 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
79 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
80 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
81 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
82 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
83 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
84 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
85 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
86 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
87 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
88 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
89 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
90 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
91 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
92 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
93 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
94 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
95 ADRA1B [6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
96 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00076 Norepinephrine [1] 22
97 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00095 Epinephrine [3] 46, 70, 96
98 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00124 Ephedrine [1] 11
99 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00255 Carvedilol [5] 6, 57, 86, 113, 210
100 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00454 Olanzapine [2] 2, 8
101 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00485 Pseudoephedrine [1] 17
102 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00511 Phenylephrine [1] 22
103 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00608 Doxazosin [2] 57, 67
104 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00610 Terazosin [1] 6
105 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00636 Amiodarone [2] 28, 127
106 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00680 Methylergometrine [3] 118, 280, 288
107 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D00996 Epinephrine [3] 46, 70, 96
108 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa [5] 5, 6, 17, 169, 170
109 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01307 Midodrine [3] 6, 17, 58
110 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01692 Alfuzosin [1] 13
111 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin [2] 6, 13
112 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02149 Epinephrine [3] 46, 70, 96
113 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02268 Ergoloid mesylate [2] 6, 206
114 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02349 Dipivefrin [1] 6
115 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D02910 Amiodarone [2] 28, 127
116 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D03415 Carvedilol [5] 6, 57, 86, 113, 210
117 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05206 Norepinephrine [1] 22
118 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05648 Pseudoephedrine [1] 17
119 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D05649 Pseudoephedrine [1] 17
120 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D06623 Olanzapine [2] 2, 8
121 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin [1] 13
122 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07874 Doxazosin [2] 57, 67
123 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08064 Ifenprodil [1] 85
124 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08207 Methylergometrine [3] 118, 280, 288
125 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine [3] 6, 17, 58
126 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08365 Phenylephrine [1] 22
127 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine [1] 17
128 ADRA1A [7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08569 Terazosin [1] 6
129 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
130 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
131 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
132 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
133 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
134 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
135 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
136 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
137 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
138 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00560 Pimozide [1] 2
139 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
140 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00606 Guanfacine [1] 193
141 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
142 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
143 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
144 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
145 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
146 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
147 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
148 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
149 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
150 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
151 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
152 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
153 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
154 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
155 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
156 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
157 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
158 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
159 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
160 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08031 Guanfacine [1] 193
161 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
162 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
163 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
164 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
165 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
166 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
167 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
168 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
169 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
170 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
171 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
172 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
173 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
174 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
175 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
176 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
177 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
178 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
179 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
180 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
181 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
182 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
183 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
184 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
185 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
186 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
187 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
188 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
189 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
190 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
191 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
192 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
193 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
194 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
195 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
196 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
197 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
198 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
199 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
200 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
201 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
202 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00076 Norepinephrine [1] 22
203 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00095 Epinephrine [3] 46, 70, 96
204 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00124 Ephedrine [1] 11
205 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00270 Chlorpromazine [1] 254
206 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00281 Clonidine [4] 6, 65, 70, 78
207 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00283 Clozapine [1] 6
208 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00405 Methyldopa [1] 323
209 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00485 Pseudoephedrine [1] 17
210 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
211 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00604 Clonidine [4] 6, 65, 70, 78
212 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00680 Methylergometrine [3] 118, 280, 288
213 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine [1] 13
214 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00789 Chlorpromazine [1] 254
215 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00996 Epinephrine [3] 46, 70, 96
216 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01008 Apraclonidine [1] 11
217 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
218 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa [5] 5, 6, 17, 169, 170
219 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine [2] 13, 90
220 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02149 Epinephrine [3] 46, 70, 96
221 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02268 Ergoloid mesylate [2] 6, 206
222 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02349 Dipivefrin [1] 6
223 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D03274 Chlorpromazine [1] 254
224 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04034 Chlorpromazine [1] 254
225 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz [2] 2, 13
226 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05206 Norepinephrine [1] 22
227 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05648 Pseudoephedrine [1] 17
228 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D05649 Pseudoephedrine [1] 17
229 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07461 Apraclonidine [1] 11
230 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine [2] 13, 90
231 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08205 Methyldopa [1] 323
232 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08207 Methylergometrine [3] 118, 280, 288
233 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine [1] 17
234 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08482 Rilmenidine [1] 8
235 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine [1] 13
236 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08685 Yohimbine [1] 6
237 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00076 Norepinephrine [1] 22
238 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00095 Epinephrine [3] 46, 70, 96
239 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00124 Ephedrine [1] 11
240 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00235 Atenolol [1] 167
241 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00255 Carvedilol [5] 6, 57, 86, 113, 210
242 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00378 Timolol [2] 157, 227
243 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00432 Nadolol [1] 6
244 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
245 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00485 Pseudoephedrine [1] 17
246 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00601 Metoprolol [6] 17, 57, 58, 113, 193, 226
247 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00603 Timolol [2] 157, 227
248 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00632 Dobutamine [3] 57, 58, 215
249 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00634 Bisoprolol [3] 67, 86, 113
250 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00636 Amiodarone [2] 28, 127
251 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00644 Esmolol [1] 58
252 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00996 Epinephrine [3] 46, 70, 96
253 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa [5] 5, 6, 17, 169, 170
254 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02149 Epinephrine [3] 46, 70, 96
255 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02342 Bisoprolol [3] 67, 86, 113
256 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02349 Dipivefrin [1] 6
257 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02358 Metoprolol [6] 17, 57, 58, 113, 193, 226
258 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02910 Amiodarone [2] 28, 127
259 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03415 Carvedilol [5] 6, 57, 86, 113, 210
260 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03879 Dobutamine [3] 57, 58, 215
261 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03880 Dobutamine [3] 57, 58, 215
262 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03881 Dobutamine [3] 57, 58, 215
263 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05011 Metoprolol [6] 17, 57, 58, 113, 193, 226
264 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05127 Nebivolol [4] 17, 85, 113, 167
265 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05206 Norepinephrine [1] 22
266 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05648 Pseudoephedrine [1] 17
267 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05649 Pseudoephedrine [1] 17
268 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07660 Celiprolol [1] 168
269 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D07916 Esmolol [1] 58
270 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
271 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08449 Pseudoephedrine [1] 17
272 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08600 Timolol [2] 157, 227
273 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [1] 22
274 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine [3] 46, 70, 96
275 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine [1] 11
276 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00255 Carvedilol [5] 6, 57, 86, 113, 210
277 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00378 Timolol [2] 157, 227
278 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00432 Nadolol [1] 6
279 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
280 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine [1] 17
281 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00603 Timolol [2] 157, 227
282 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00687 Salmeterol [1] 299
283 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00688 Terbutaline [1] 118
284 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine [3] 46, 70, 96
285 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
286 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01373 Formoterol [3] 85, 228, 299
287 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol [14] 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
288 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine [3] 46, 70, 96
289 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02151 Tulobuterol [1] 6
290 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
291 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D03415 Carvedilol [5] 6, 57, 86, 113, 210
292 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine [1] 22
293 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05277 Formoterol [3] 85, 228, 299
294 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine [1] 17
295 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine [1] 17
296 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05792 Salmeterol [1] 299
297 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol [5] 1, 2, 6, 13, 256
298 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07990 Formoterol [3] 85, 228, 299
299 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine [1] 13
300 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08124 Levosalbutamol [1] 49
301 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
302 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine [1] 17
303 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08570 Terbutaline [1] 118
304 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08600 Timolol [2] 157, 227
305 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00076 Norepinephrine [1] 22
306 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00095 Epinephrine [3] 46, 70, 96
307 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00124 Ephedrine [1] 11
308 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
309 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00485 Pseudoephedrine [1] 17
310 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00996 Epinephrine [3] 46, 70, 96
311 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa [5] 5, 6, 17, 169, 170
312 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02149 Epinephrine [3] 46, 70, 96
313 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02349 Dipivefrin [1] 6
314 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05206 Norepinephrine [1] 22
315 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05648 Pseudoephedrine [1] 17
316 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D05649 Pseudoephedrine [1] 17
317 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
318 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine [1] 17
319 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron [4] 6, 13, 53, 226
320 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril [8] 6, 17, 46, 86, 96, 97, 107, 271
321 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00362 Lisinopril [7] 19, 46, 49, 66, 67, 113, 222
322 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00421 Ramipril [7] 46, 49, 66, 67, 113, 218, 257
323 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00459 Quinapril [1] 19
324 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00620 Benazepril [4] 49, 57, 218, 224
325 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00621 Enalapril [6] 19, 46, 66, 113, 210, 222
326 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00623 Moexipril [1] 93
327 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00624 Perindopril [4] 58, 113, 167, 222
328 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D01069 Cilazapril [1] 66
329 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D03752 Quinapril [1] 19
330 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D03753 Perindopril [4] 58, 113, 167, 222
331 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07499 Benazepril [4] 49, 57, 218, 224
332 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07699 Cilazapril [1] 66
333 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D07892 Enalapril [6] 19, 46, 66, 113, 210, 222
334 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08068 Imidapril [1] 67
335 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08131 Lisinopril [7] 19, 46, 49, 66, 67, 113, 222
336 ACE [6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D08225 Moexipril [1] 93
337 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
338 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
339 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00400 Valsartan [7] 57, 58, 66, 75, 218, 222, 224
340 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan cilexetil [1] 67
341 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00522 Candesartan [2] 58, 67
342 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00523 Irbesartan [4] 66, 167, 168, 222
343 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00626 Candesartan cilexetil [1] 67
344 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00627 Telmisartan [2] 66, 67
345 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
346 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
347 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D11776 Sparsentan [3] 66, 218, 222
348 AGTR2 [3] Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D00150 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
349 AGTR2 [3] Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D02014 Angiotensin II [7] 17, 19, 46, 66, 86, 222, 224
350 ABAT [7] Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
351 ABAT [7] Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00535 Vigabatrin [2] 145, 158
352 ALAS1 [4] Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors D10003 Hemin [1] 254
353 ALAS1 [4] Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors D11702 Givosiran [1] 254
354 ALAS2 [4] Glycine, serine and threonine metabolism, Porphyrin metabolism, Metabolic pathways, Biosynthesis of cofactors D10003 Hemin [1] 254
355 ABCD1 [2] ABC transporters, Peroxisome D12150 Elivaldogene autotemcel [1] 20
356 ALK [3] Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09731 Crizotinib [1] 34
357 ALK [3] Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10866 Brigatinib [1] 34
358 ALOX5 [6] Arachidonic acid metabolism, Metabolic pathways, Fc epsilon RI signaling pathway, Serotonergic synapse, Ovarian steroidogenesis, Toxoplasmosis D00414 Zileuton [3] 85, 160, 164
359 ALOX5 [6] Arachidonic acid metabolism, Metabolic pathways, Fc epsilon RI signaling pathway, Serotonergic synapse, Ovarian steroidogenesis, Toxoplasmosis D01773 Oxatomide [1] 113
360 ALPL [4] Thiamine metabolism, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors D10595 Asfotase alfa [1] 172
361 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D01441 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
362 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D03252 Bosutinib [2] 2, 67
363 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D03658 Dasatinib [2] 51, 85
364 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D06414 Dasatinib [2] 51, 85
365 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08066 Imatinib [12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
366 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08953 Nilotinib [5] 6, 8, 34, 51, 86
367 ABL1 [11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D09664 Saracatinib [3] 6, 89, 272
368 ANGPTL3 [1] Cholesterol metabolism D11753 Evinacumab [1] 79
369 AMY2A [5] Starch and sucrose metabolism, Metabolic pathways, Salivary secretion, Pancreatic secretion, Carbohydrate digestion and absorption D00216 Acarbose [1] 298
370 AMY2B [5] Starch and sucrose metabolism, Metabolic pathways, Salivary secretion, Pancreatic secretion, Carbohydrate digestion and absorption D00216 Acarbose [1] 298
371 ANPEP [4] Glutathione metabolism, Metabolic pathways, Renin-angiotensin system, Hematopoietic cell lineage D00087 Ubenimex [1] 86
372 APCS - D11464 Miridesap [1] 28
373 APCS - D11471 Dezamizumab [1] 28
374 APOC3 [2] PPAR signaling pathway, Cholesterol metabolism D11648 Volanesorsen [1] 265
375 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00075 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
376 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00289 Danazol [5] 60, 63, 64, 65, 285
377 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00444 Stanozolol [1] 60
378 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00462 Oxandrolone [2] 211, 285
379 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00586 Flutamide [1] 81
380 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00955 Nandrolone decanoate [2] 60, 85
381 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00957 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
382 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
383 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone enanthate [2] 13, 113
384 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00959 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
385 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00959 Testosterone propionate [1] 113
386 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D03338 Calusterone [3] 2, 46, 71
387 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06085 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
388 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone [9] 1, 2, 3, 13, 60, 76, 78, 113, 265
389 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone undecanoate [2] 13, 60
390 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08250 Nandrolone [2] 60, 85
391 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08409 Prasterone [6] 49, 53, 83, 86, 96, 113
392 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08573 Testosterone decanoate [1] 113
393 AR [4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D08574 Testosterone phenylpropionate [1] 113
394 ARSB [3] Glycosaminoglycan degradation, Metabolic pathways, Lysosome D06565 Galsulfase [1] 19
395 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D00487 Pyridostigmine [4] 3, 6, 11, 256
396 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D00670 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
397 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D02068 Tacrine [3] 46, 271, 299
398 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D02173 Galantamine [2] 6, 127
399 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D02558 Rivastigmine [3] 5, 6, 13
400 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine [3] 5, 6, 13
401 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D04292 Galantamine [2] 6, 127
402 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil [9] 5, 6, 13, 46, 78, 124, 127, 156, 206
403 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D08261 Neostigmine [1] 11
404 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D08555 Tacrine [3] 46, 271, 299
405 ACHE [2] Glycerophospholipid metabolism, Cholinergic synapse D09917 Latrepirdine [1] 8
406 ATP1A1 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin [1] 299
407 ATP1A1 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin [3] 8, 46, 210
408 ATP1A2 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin [1] 299
409 ATP1A2 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin [3] 8, 46, 210
410 ATP1A3 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin [1] 299
411 ATP1A3 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin [3] 8, 46, 210
412 ATP1A4 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00297 Digitoxin [1] 299
413 ATP1A4 [18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption D00298 Digoxin [3] 8, 46, 210
414 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00355 Lansoprazole [7] 63, 71, 85, 98, 166, 222, 299
415 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
416 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00724 Rabeprazole [2] 2, 51
417 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
418 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
419 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D02593 Pantoprazole [2] 13, 65
420 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
421 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
422 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
423 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole [2] 13, 65
424 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
425 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08463 Rabeprazole [2] 2, 51
426 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08903 Dexlansoprazole [1] 98
427 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
428 ATP4A [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D11784 Vonoprazan [2] 63, 98
429 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00355 Lansoprazole [7] 63, 71, 85, 98, 166, 222, 299
430 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
431 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00724 Rabeprazole [2] 2, 51
432 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
433 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
434 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D02593 Pantoprazole [2] 13, 65
435 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
436 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
437 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole [16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
438 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole [2] 13, 65
439 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
440 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08463 Rabeprazole [2] 2, 51
441 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D08903 Dexlansoprazole [1] 98
442 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole [8] 13, 46, 86, 98, 107, 113, 298, 299
443 ATP4B [4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D11784 Vonoprazan [2] 63, 98
444 APH1A [2] Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil [1] 13
445 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
446 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D01236 Conivaptan [1] 86
447 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
448 AVPR1A [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D07748 Conivaptan [1] 86
449 AVPR1B [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D00101 Vasopressin [1] 210
450 AVPR1B [4] Calcium signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction D06672 Terlipressin [1] 299
451 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00101 Vasopressin [1] 210
452 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D00291 Desmopressin [6] 6, 64, 72, 75, 225, 288
453 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D01213 Tolvaptan [3] 67, 72, 225
454 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D01236 Conivaptan [1] 86
455 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D02235 Desmopressin [6] 6, 64, 72, 75, 225, 288
456 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D04752 Lixivaptan [1] 67
457 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D06672 Terlipressin [1] 299
458 AVPR2 [3] Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption D07748 Conivaptan [1] 86
459 AXL [1] EGFR tyrosine kinase inhibitor resistance D10062 Cabozantinib [1] 34
460 ABCC8 [3] ABC transporters, Insulin secretion, Type II diabetes mellitus D00294 Diazoxide [2] 13, 193
461 ABCC8 [3] ABC transporters, Insulin secretion, Type II diabetes mellitus D00418 Minoxidil [1] 179
462 ABCC8 [3] ABC transporters, Insulin secretion, Type II diabetes mellitus D00594 Repaglinide [3] 6, 21, 299
463 ADAM17 [4] Notch signaling pathway, Alzheimer disease, Epithelial cell signaling in Helicobacter pylori infection, Coronavirus disease - COVID-19 D08859 Apratastat [1] 46
464 ALDH5A1 [3] Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid [17] 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
465 AOC3 [5] Glycine, serine and threonine metabolism, Tyrosine metabolism, Phenylalanine metabolism, beta-Alanine metabolism, Metabolic pathways D08044 Hydralazine [1] 67
466 ACVR2A [4] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D09670 Sotatercept [2] 86, 284
467 ACVR2A [4] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D10620 Bimagrumab [1] 15
468 ACVR2B [4] Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis D10620 Bimagrumab [1] 15